One Pharma Company Suddenly Says It Already Has a "Vaccine" in Testing for New, "Horrible" Variant

Posted by Kyle Becker for Becker News

The Omicron variant, the latest Covid mutation grabbing international headlines, is already causing a devastating ripple effect throughout the world. Global authorities in the U.K. and the E.U. are tightening their borders in anticipation of another Covid wave.

In the United States, New York’s governor Kathy Hochul has already canceled elective surgeries in the state citing the Omicron variant, even as the transmissibility and deadliness of this latest Covid mutation are unknown. The variant is believed to have originated in Botswana, and may be playing a role in a Covid surge in South Africa. The variant has been identified in Botswana, South Africa, Hong Kong, and Amsterdam in The Netherlands.

Pfizer-BioNTech, fresh off sky-high profits off of its government-mandated ‘vaccines,’ is already mullying a ‘future relaunch‘ of a Covid-19 vaccine to deal with the Omicron variant. It looks like a lesser-known pharmaceutical company, Novavax, however, may beat it to the punch.

Novavax said on Friday it has “started working on a version of its COVID-19 vaccine to target the variant detected in South Africa” and “would have the shot ready for testing and manufacturing in the next few weeks,” Reuters reported.

“The company’s COVID-19 shot contains an actual version of the virus’ spike protein that cannot cause disease but can trigger the immune system,” Reuters noted. “The vaccine developer said it had started developing a spike protein specifically based on the known genetic sequence of the variant, B.1.1.529.”

The report notes that Novavax’s vaccine received its first emergency use approval earlier this month in Indonesia, followed by the Philippines.

“The company has said it is on track to file for U.S. approval by the end of the year,” the report continued. “It has also filed for approvals with the European Medicines Agency as well as in Canada.”

Novavax’s statement indicates a potential continuation of the track record of Covid vaccines that are patented and developed ‘too quickly.’ Before SARS-CoV-2 burst onto the global scene in December 2019, it was expected that a vaccine took years of testing and development.

[WATCH] Prof. Tulio de Oliveira gives a summary of the new #COVID19 variant, the B.1.1.529, that has been detected in South Africa.#Newzroom405 pic.twitter.com/yfcilLCUPZ
— Newzroom Afrika (@Newzroom405) November 25, 2021

Suddenly, it takes almost no time at all to produce a so-called “vaccine” that is actually just a prophylactic therapeutic, which subsequently wears off in months and requires “boosters.” It is reminiscent of the manner that China rapidly produced a patent for a vaccine after international authorities learned of Covid-19, which the Communist Chinese Party apparently knew about and kept hidden from the world since May 2019.